Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
RegulatoryWatchMinormateriality 56 out of 100
What happened
FactPendency of Litigation(s)/dispute(s) or the outcome impacting the Company.
Why it matters
CapitSignal interpretationLitigation creates a contingent liability that is not in reported profit until it crystallises.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Guidance
WithdrawnEarlierFY27
With an EBIDTA of Rs. 180-200 cr.
NowFY27
Our International Business is well on its way to achieve Rs. 1,000 cr. revenue by 2029/ 2030
Change
FactGuidance withdrawn
Implication
CapitSignal interpretationThe earlier statement provided a specific EBITDA target of Rs. 180-200 cr., while the current statement no longer mentions this target and instead focuses on revenue expectations for the International Business by 2029/2030.confidence 90%
Watch next
Fact- Amount claimed against the company
- Whether a provision has been made
- Next hearing or order date
- We see an EBIDTA potential of at least Rs. 50 cr. p.a. from the additional market opportunity (management committed by FY27)
- VE A NET-DEBT-TO-EBIDTA RATIO OF < 1.5x BY DEC 2026 (management committed by Q4 FY26)
Evidence
- Eris Lifesciences Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company(opens the original filing in a new tab)
- Earlier statement · FY27
- Latest statement · FY27
- Earlier statement · FY27
How CapitSignal classified this
- Reasoning:
- LITIGATION base 56; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%